Bill's practice focuses on patent prosecution, with a particular emphasis on pharmaceutical products and targets as well as other small molecules, including dyes, probes, and binding agents. He leverages experience in the corporate setting to provide clients with a business-based, product-driven approach to all of his IP legal services, including the strategic development of patent portfolios, due diligence reviews of targeted companies and technology, and comparative evaluations of competitive patented technologies. Bill also procures global patent protection for pharmaceutical inventions and focuses on product protection strategies involving formulations, drug delivery technologies, and dosing methods.

Prior to joining the IP team at Mintz Levin, Bill was a partner in the Bay Area office of a large, international law firm. He also served as in-house patent counsel for Tularik Inc. (now part of Amgen, Inc.), a company involved in the discovery of compounds for the regulation of gene expression.

Earlier Bill worked as a senior research scientist and project leader for FMC Corporation and Dow Chemical Company/DowElanco, where his research involved the design and synthesis of small molecule regulators of biological processes. Bill's doctoral thesis, conducted under the direction of Professor Paul A. Bartlett at UC Berkeley, concerned the design and synthesis of transition-state analogs as inhibitors as peptidases.